| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antibiotic resistance incidence or proportions: where does the greatest burden lie?
|
Walker, Morgan K
|
|
|
24 |
12 |
p. 1291-1293
|
artikel
|
| 2 |
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study
|
McMahon, Robert
|
|
|
24 |
12 |
p. 1383-1392
|
artikel
|
| 3 |
Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings
|
Kwizera, Richard
|
|
|
24 |
12 |
p. e782-e793
|
artikel
|
| 4 |
Assessing the real-world effectiveness of the rVSV-ZEBOV vaccine
|
Williamson, Deborah A
|
|
|
24 |
12 |
p. 1295-1296
|
artikel
|
| 5 |
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations
|
Marques, Ernesto T A
|
|
|
24 |
12 |
p. 1298-1299
|
artikel
|
| 6 |
Clinical trials versus the real world in tuberculosis control
|
The Lancet Infectious Diseases,
|
|
|
24 |
12 |
p. 1287
|
artikel
|
| 7 |
Correction to Lancet Infect Dis 2021; 21: 823–33
|
|
|
|
24 |
12 |
p. e737
|
artikel
|
| 8 |
Correction to Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7
|
|
|
|
24 |
12 |
p. e737
|
artikel
|
| 9 |
Correction to Lancet Infect Dis 2024; published online Oct 10. https://doi.org/10.1016/S1473-3099(24)00507-3
|
|
|
|
24 |
12 |
p. e737
|
artikel
|
| 10 |
Correction to Lancet Infect Dis 2024; published online Sept 27. https://doi.org.10.1016/S1473-3099(24)00618-2
|
|
|
|
24 |
12 |
p. e737
|
artikel
|
| 11 |
COVID-19 in South Asia
|
Pascal, Genevieve
|
|
|
24 |
12 |
p. 1306
|
artikel
|
| 12 |
CRISPR-Cas3-armed bacteriophages for drug-resistant bacteria
|
Merabishvili, Maya
|
|
|
24 |
12 |
p. 1289-1291
|
artikel
|
| 13 |
Ebola virus disease mathematical models and epidemiological parameters: a systematic review
|
Nash, Rebecca K
|
|
|
24 |
12 |
p. e762-e773
|
artikel
|
| 14 |
Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study
|
Meakin, Sophie
|
|
|
24 |
12 |
p. 1357-1365
|
artikel
|
| 15 |
Gilead under fire over HIV drug licensing
|
Holt, Ed
|
|
|
24 |
12 |
p. e742
|
artikel
|
| 16 |
Highlights of IDWeek 2024
|
Hall, Phoebe
|
|
|
24 |
12 |
p. e738
|
artikel
|
| 17 |
How to face a pandemic
|
McQuillan, Cahal
|
|
|
24 |
12 |
p. 1308
|
artikel
|
| 18 |
Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC
|
Arora, Prerna
|
|
|
24 |
12 |
p. e732-e733
|
artikel
|
| 19 |
Infectious disease surveillance update
|
McQuillan, Cahal
|
|
|
24 |
12 |
p. e745
|
artikel
|
| 20 |
Investigating the effect of enhanced cleaning and disinfection of shared medical equipment on health-care-associated infections in Australia (CLEEN): a stepped-wedge, cluster randomised, controlled trial
|
Browne, Katrina
|
|
|
24 |
12 |
p. 1347-1356
|
artikel
|
| 21 |
Justyna Kowalska—reaching underserved people with HIV
|
Kirby, Tony
|
|
|
24 |
12 |
p. 1303
|
artikel
|
| 22 |
Local communities
|
Dunsmuir, Henrietta
|
|
|
24 |
12 |
p. 1307
|
artikel
|
| 23 |
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine
|
Oda, Yoshiaki
|
|
|
24 |
12 |
p. e729-e731
|
artikel
|
| 24 |
Mpox control strategies: using behaviour change to complement, not replace, vaccination
|
Shamier, Marc C
|
|
|
24 |
12 |
p. 1288-1289
|
artikel
|
| 25 |
Outbreak of Marburg virus disease in Rwanda
|
Nakkazi, Esther
|
|
|
24 |
12 |
p. e740
|
artikel
|
| 26 |
Pakistan, India, and Viet Nam eliminate trachoma
|
Jesudason, Timothy
|
|
|
24 |
12 |
p. e741
|
artikel
|
| 27 |
Preconception immunisation to prevent pregnancy-associated malaria
|
Yanow, Stephanie K
|
|
|
24 |
12 |
p. 1296-1298
|
artikel
|
| 28 |
Predictable excess hepatotoxicity in the SimpliciTB trial
|
Burman, William
|
|
|
24 |
12 |
p. e727
|
artikel
|
| 29 |
Predictable excess hepatotoxicity in the SimpliciTB trial – Authors’ reply
|
Cevik, Muge
|
|
|
24 |
12 |
p. e728
|
artikel
|
| 30 |
Preparing for the rapid research response to the possible vertical transmission of Oropouche virus: lessons from a decade of congenital Zika research
|
Brickley, Elizabeth B
|
|
|
24 |
12 |
p. e725-e726
|
artikel
|
| 31 |
Pui-Ying Iroh Tam
|
Bagcchi, Sanjeet
|
|
|
24 |
12 |
p. 1302
|
artikel
|
| 32 |
Research in brief
|
Venkatesan, Priya
|
|
|
24 |
12 |
p. e746
|
artikel
|
| 33 |
Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
|
Diawara, Halimatou
|
|
|
24 |
12 |
p. 1366-1382
|
artikel
|
| 34 |
Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial
|
Modjarrad, Kayvon
|
|
|
24 |
12 |
p. 1393-1402
|
artikel
|
| 35 |
Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial
|
Kim, Paul
|
|
|
24 |
12 |
p. 1319-1332
|
artikel
|
| 36 |
Serious threat of antimicrobial resistance in Ukraine
|
Holt, Ed
|
|
|
24 |
12 |
p. e739
|
artikel
|
| 37 |
Subretinal and brain abscesses caused by Streptococcus intermedius
|
Poslenski, Alexis
|
|
|
24 |
12 |
p. e794
|
artikel
|
| 38 |
Success of the CLEEN study
|
Gould, Dinah
|
|
|
24 |
12 |
p. 1293-1294
|
artikel
|
| 39 |
Temporary adaptations to sexual behaviour during the mpox outbreak in 23 countries in Europe and the Americas: findings from a retrospective cross-sectional online survey
|
Prochazka, Mateo
|
|
|
24 |
12 |
p. 1309-1318
|
artikel
|
| 40 |
The dangers of medication sharing at private sex parties
|
Mimiaga, Matthew J
|
|
|
24 |
12 |
p. e734-e735
|
artikel
|
| 41 |
The panzootic spread of highly pathogenic avian influenza H5N1 sublineage 2.3.4.4b: a critical appraisal of One Health preparedness and prevention
|
Koopmans, Marion P G
|
|
|
24 |
12 |
p. e774-e781
|
artikel
|
| 42 |
The promising prospects of a new yellow fever vaccine
|
Roukens, Anna H E
|
|
|
24 |
12 |
p. 1299-1301
|
artikel
|
| 43 |
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
|
Terstappen, Jonne
|
|
|
24 |
12 |
p. e747-e761
|
artikel
|
| 44 |
Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007–22)
|
Pham, Thi Mui
|
|
|
24 |
12 |
p. 1333-1346
|
artikel
|
| 45 |
Tuberculosis reclaims position as top infectious killer
|
Burki, Talha
|
|
|
24 |
12 |
p. e743-e744
|
artikel
|
| 46 |
Two pandemics, a shared lesson
|
Starbuck, Emma
|
|
|
24 |
12 |
p. 1305
|
artikel
|
| 47 |
Vaccine hesitancy on stage
|
Burki, Talha
|
|
|
24 |
12 |
p. 1304
|
artikel
|
| 48 |
Virological characteristics of the SARS-CoV-2 XEC variant
|
Kaku, Yu
|
|
|
24 |
12 |
p. e736
|
artikel
|
Tijdschrift beschrijving